İmdat Eroğlu, Medical Oncology Fellow at Gazi University, shared on LinkedIn:
“Can we improve prognostic stratification for glioblastoma when molecular testing is not universally available?
I’m happy to share our latest publication in Future Oncology published by Taylor and Francis Group – Taylor and Francis Research Insights.
The novel RANO risk score has significantly improved prognostic stratification for patients with IDH-wildtype glioblastoma. However, MGMT promoter methylation testing remains inaccessible in many parts of the world, limiting its global applicability.
In our pilot, hypothesis-generating study, we evaluated a RANO-adapted clinical score excluding MGMT promoter methylation while preserving the original scoring framework, and it still demonstrated strong prognostic performance for both overall and progression-free survival. We hope this pragmatic approach will stimulate further validation studies and contribute to the development of more equitable and globally applicable prognostic tools, particularly for resource-limited settings.
Many thanks to all my co-authors, and especially to my professors at the Gazi Üniversitesi Medical Oncology Department, for their invaluable guidance, support, and collaboration throughout this work.”
Title: A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing
Authors: Ashley F. Sanchez Sevilla Uruchurtu, Audrey Y. Su, Harshita Ganga, Shengliang Zhang, Ameen Raissi, Kevin Kwon, Tej Tummala, Tyler Roady, Jacqueline Moreno, Patrycja M. Dubielecka-Szczerba, Christopher G. Azzoli, Wafik S. El-Deiry
Other articles featuring İmdat Eroğlu on OncoDaily.